Intellia Therapeutics

biotechnology company

Based in MA

🤖

AI Overview

With $390K in lobbying spend across 13 quarterly filings, Intellia Therapeutics is an active lobbying client. Their lobbying covers 1 issue area. Active from 2019 to 2022.

$390K

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2019	$70K
2020	$200K
2021	$120K
2022	$0

Issues Lobbied

Health Issues

Lobbying Firms

Crossroads Strategies, LLC

Lobbyists

Katherine Dapper Mathew Lapinski Marc Numedahl Jason Van Pelt Jason Gleason Shay Hancock Brittany Hernandez

Government Agencies Targeted

These are the government entities that Intellia Therapeutics disclosed contacting in their lobbying filings.

Executive Office of the President (EOP)HOUSE OF REPRESENTATIVESOffice of the Vice President of the United StatesSENATEFood & Drug Administration (FDA)

View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues

Education and advocacy related to gene therapy.

Education and advocacy related to gene therapy;

H.R.3, Lower Drug Costs Now Act of 2019;

S.2543, Prescription Drug Pricing Reduction Act of 2019;

H.R.19, Lower Costs, More Cures Act of 2019.

Education and advocacy related to gene therapy.

Education around COVID-19 therapies.

H.R.3, Lower Drug Costs Now Act of 2019.

S.2543, Prescription Drug Pricing Reduction Act of 2019.

H.R.19, Lower C